NCT02814838View on ClinicalTrials.gov

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

May 15, 2019

Study Completion Date

May 15, 2019

Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
DRUG

Ladarixin

Ladarixin oral capsule

DRUG

Placebo

Placebo oral capsule

Trial Locations (8)

1090

Universitair Ziekenhuis Brussel Diabetes Clinic, Brussels

3000

Universitair Ziekenhuis Leuven Campus Gasthuisberg Endocrinology, Leuven

20132

Internal Medicine - Diabetes & Endocrinology Unit, San Raffaele Hospital Milan, Milan

32392

Med. Klinik und Poliklinik 3, Universitätsklinikum Giessen und Marburg GmbH, Giessen

48145

Zentrum für Diabetes und Gefäßerkrankungen, Münster

70124

Università Aldo Moro-Ospedale Policlinico, Bari

88554

Presidio Policlinico di Monserrato, Cagliari

00128

Unità Operativa Complessa di Endocrinologia e Dialettologia. Università Campus Bio-Medico di Roma, Rome

All Listed Sponsors
lead

Dompé Farmaceutici S.p.A

INDUSTRY

NCT02814838 - A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes | Biotech Hunter | Biotech Hunter